Xencor Inc Sustainability Reports

Xencor, Inc. is a clinical-stage biopharmaceutical company that discovers and develops engineered monoclonal antibodies and biotherapeutic drug candidates. The company utilizes its proprietary XmAb technology platform to optimize antibodies for treating patients with cancer and autoimmune diseases.

Sector: Manufacturing

Country: United States

Exchange: Nasdaq

LEI: 549300V5IF65437JKG30

FIGI: BBG0026ZG4X9

14 reports from 2014 to 2025

• Xencor Inc 2025 Form 10-K
• Xencor Inc 2024 Form 10-K
• Xencor Inc 2023 Form 10-K
• Xencor Inc 2022 Corporate Responsibility Statement
• Xencor Inc 2022 Form 10-K